Tonix Pharmaceuticals (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, up from $2 million in the year-ago period, driven by approximately $11 million in net sales of TONMYA. The fibromyalgia treatment recorded 12,592 total prescriptions during the quarter, up 100% sequentially, while new patient prescriptions increased 36% and refills rose 207%. TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare and Medicaid channels, with coverage expected to reach approximately 145 million lives when a managed Medicare agreement takes effect Jan. 1, 2027.
Tonix also continued advancing its clinical pipeline, enrolling the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder and preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents and said its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027.
To view the full press release, visit https://nnw.fm/6Yytj
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer